Search Results - "Kraut, H."

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein by HOFMEISTER, Craig C, XIAOXIA YANG, JIA JI, SCHAAF, Larry J, BENSON, Don M, KRAUT, Eric H, HICKS, William J, CHAN, Kenneth K, CHEN, Ching-Shih, FARAG, Sherif S, GREVER, Michael R, BYRD, John C, PICHIORRI, Flavia, PHELPS, Mitch A, PING CHEN, ROZEWSKI, Darlene M, JOHNSON, Amy J, LEE, Seungsoo, ZHONGFA LIU, GARR, Celia L, HADE, Erinn M

“…Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical…”
Get full text

Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders by LIN, Thomas S, BLUM, Kristie A, SCHAAF, Larry J, GREVER, Michael R, BYRD, John C, BETH FISCHER, Diane, MITCHELL, Sarah M, RUPPERT, Amy S, PORCU, Pierluigi, KRAUT, Eric H, BAIOCCHI, Robert A, MORAN, Mollie E, JOHNSON, Amy J

“…Flavopiridol downmodulates antiapoptotic proteins associated with resistance to fludarabine and rituximab and is effective against p53-mutated chronic…”
Get full text

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020 by Becker, Pamela Sue, Griffiths, Elizabeth A, Alwan, Laura M, Bachiashvili, Kimo, Brown, Anna, Cool, Rita, Curtin, Peter, Dinner, Shira, Gojo, Ivana, Hicks, Ashley, Kallam, Avyakta, Kidwai, Wajih Zaheer, Kloth, Dwight D, Kraut, Eric H, Landsburg, Daniel, Lyman, Gary H, Miller, Ryan, Mukherjee, Sudipto, Patel, Shiven, Perez, Lia E, Poust, Adam, Rampal, Raajit, Rosovsky, Rachel, Roy, Vivek, Rugo, Hope S, Shayani, Sepideh, Vasu, Sumithira, Wadleigh, Martha, Westbrook, Kelly, Westervelt, Peter, Burns, Jennifer, Keller, Jennifer, Pluchino, Lenora A

“…Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic…”
Get more information

An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura by Cataland, Spero R., Jin, Ming, Ferketich, Amy K., Kennedy, Melanie S., Kraut, Eric H., George, James N., Wu, Haifeng M.

“…Summary We present the results of two consecutively performed cohort studies that evaluated the clinical effects of corticosteroids or ciclosporin as an…”
Get full text

Bleeding and bruising: a diagnostic work-up by Ballas, Michael, Kraut, Erich H

“…Primary care physicians are often asked about easy bruising, excessive bleeding, or risk of bleeding before surgery. A thorough history, including a family…”
Get full text

Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus by Mauer, A.M., Kraut, E.H., Krauss, S.A., Ansari, R.H., Kasza, K., Szeto, L., Vokes, E.E.

“…Background: The aim of the study was to evaluate the efficacy and tolerability of the combination of oxaliplatin, fluorouracil and leucovorin in patients with…”
Get full text

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia by Marcucci, Guido, Byrd, John C., Dai, Guowei, Klisovic, Marko I., Kourlas, Peter J., Young, Donn C., Cataland, Spero R., Fisher, Diane B., Lucas, David, Chan, Kenneth K., Porcu, Pierluigi, Lin, Zhong-Pin, Farag, Sherif F., Frankel, Stanley R., Zwiebel, James A., Kraut, Eric H., Balcerzak, Stanley P., Bloomfield, Clara D., Grever, Michael R., Caligiuri, Michael A.

“…Overexpression of Bcl-2 is a potential mechanism for chemoresistance in acute leukemia and has been associated with unfavorable clinical outcome. We…”
Get full text

Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review by KRAUT, E. H., ALEDORT, L. M., ARKIN, S., STINE, K. C., WONG, W.-Y.

“…Strategies for the management of perioperative bleeding in patients with haemophilia and inhibitors have evolved rapidly as a result of the development of the…”
Get full text

A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors by BEKAII-SAAB, Tanios S, JING LIU, CHAN, Kenneth K, BALCERZAK, Stanley P, IVY, Percy S, GREVER, Michael R, KRAUT, Eric H

“…Purpose: Oxaliplatin and paclitaxel are widely used in treating solid tumors. We designed a phase I study with the purpose of determining the maximal tolerated…”
Get full text

Clinical manifestations and infectious complications of hairy-cell leukaemia by Kraut, Eric H

“…Hairy-cell leukaemia is an indolent lymphoproliferative malignancy characterized by infiltration of the bone marrow, liver, spleen, and occasionally lymph…”
Get full text

Experience With Pre-procedural Hemostatic Medications versus Platelet Transfusion in Patients With Platelet Storage Pool Deficiency by Lundy, Katharine A., Rabatin, Abigail, Davidson, Erica R., Li, Junan, Snider, Melissa J., Kraut, Eric H.

“…Background Storage pool deficiency (SPD) is a rare bleeding disorder characterized by reduction in the number of delta granules within platelets, interfering…”
Get full text

Minimal SARS-CoV-2 Transmission After Implementation of a Comprehensive Mitigation Strategy at a School - New Jersey, August 20-November 27, 2020 by Volpp, Kevin G, Kraut, Bruce H, Ghosh, Smita, Neatherlin, John

“…During fall 2020, many U.S. kindergarten through grade 12 (K-12) schools closed campuses and instituted remote learning to limit in-school transmission of…”
Get full text

Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease by Raman, SV, Simonetti, OP, Cataland, , SR, Kraut, EH

“…Division of Cardiovascular Medicine, The Ohio State University 473 W. 12th Avenue, Suite 200, Columbus, OH 43210, USA. Raman.1@osu.edu BACKGROUND AND…”
Get full text

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer by SAAD, Everardo D, KRAUT, Eric H, HOFF, Paulo M, MOORE, Dennis F, JONES, Donnah, PAZDUR, Richard, ABBRUZZESE, James L

“…Dolastatin-10 is a potent inhibitor of microtubule assembly derived from the sea hare, which displayed significant antitumor activity in preclinical models. We…”
Get full text

A Case Report of Siblings with Dystonia: A Potential Link Between DYT11 Mutation and Platelet Dysfunction by Damante, Mark, Ganguly, Ranjit, Huntoon, Kristin, Kraut, Eric, Deogaonkar, Milind

“…Myoclonus-dystonia syndrome (MDS) is an autosomal dominant disorder due to a mutated epsilon-sarcoglycan gene (SGCE) at the dystonia 11 (DYT11) locus on…”
Get full text

Cancer- and chemotherapy-induced anemia by Rodgers, 3rd, George M, Becker, Pamela Sue, Blinder, Morey, Cella, David, Chanan-Khan, Asher, Cleeland, Charles, Coccia, Peter F, Djulbegovic, Benjamin, Gilreath, Jeffrey A, Kraut, Eric H, Matulonis, Ursula A, Millenson, Michael M, Reinke, Denise, Rosenthal, Joseph, Schwartz, Rowena N, Soff, Gerald, Stein, Richard S, Vlahovic, Gordana, Weir, 3rd, Alva B

“…Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care…”
Get more information

Extended Use of Intravenous Bisphosphonate Therapy for the Prevention of Skeletal Complications in Patients with Cancer by Crawford, Brooke S., McNulty, Robert M., Kraut, Eric H., Turowski, Robert C.

“…ABSTRACT Purpose: To evaluate the incidence of skeletal complications in patients with multiple myeloma, and metastatic breast, prostate, or lung cancers, when…”
Get full text

Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin by KRAUT, E. H, GREVER, M. R, BOURONCLE, B. A

“…Twenty-four patients with advanced hairy cell leukemia treated with 2'-deoxycoformycin (dCF) were studied after achieving complete remission to determine the…”
Get full text

Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study by Kraut, E H, Crowley, J J, Wade, J L, Laufman, L R, Alsina, M, Taylor, S A, Salmon, S E

“…Topotecan is a topoisomerase I inhibitor with antitumor activity against hematologic and solid tumor malignancies. We evaluated its activity in refractory and…”
Get more information

A phase I trial of flavopiridol in relapsed multiple myeloma by Hofmeister, Craig C., Poi, Ming, Bowers, Mindy A., Zhao, Weiqiang, Phelps, Mitch A., Benson, Don M., Kraut, Eric H., Farag, Sherif, Efebera, Yvonne A., Sexton, Jennifer, Lin, Thomas S., Grever, Michael, Byrd, John C.

“…Purpose Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and…”
Get full text